ethosuximide has been researched along with Ache in 4 studies
Ethosuximide: An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.
ethosuximide : A dicarboximide that is pyrrolidine-2,5-dione in which the hydrogens at position 3 are substituted by one methyl and one ethyl group. An antiepileptic, it is used in the treatment of absence seizures and may be used for myoclonic seizures, but is ineffective against tonic-clonic seizures.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ethosuximide was halted and due to the severe symptoms, treatment with both prednisolone and intravenous iloprost was commenced." | 5.72 | Severe Raynaud's phenomenon from ethosuximide raised concern over possible onset of systemic vasculitis: a case report. ( Berntson, L; Liminga, G, 2022) |
| " The initial anticonvulsant screening was performed in mice (ip) using the 'classical' maximal electroshock (MES) and subcutaneous pentylenetetrazole (scPTZ) tests as well as in the six-Hertz (6Hz) model of pharmacoresistant limbic seizures." | 3.83 | New hybrid molecules with anticonvulsant and antinociceptive activity derived from 3-methyl- or 3,3-dimethyl-1-[1-oxo-1-(4-phenylpiperazin-1-yl)propan-2-yl]pyrrolidine-2,5-diones. ( Abram, M; Andres-Mach, M; Kamiński, K; Obniska, J; Rapacz, A; Zagaja, M; Łuszczki, JJ, 2016) |
| "Ethosuximide was halted and due to the severe symptoms, treatment with both prednisolone and intravenous iloprost was commenced." | 1.72 | Severe Raynaud's phenomenon from ethosuximide raised concern over possible onset of systemic vasculitis: a case report. ( Berntson, L; Liminga, G, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yogeeswari, P | 1 |
| Ragavendran, JV | 1 |
| Sriram, D | 1 |
| Nageswari, Y | 1 |
| Kavya, R | 1 |
| Sreevatsan, N | 1 |
| Vanitha, K | 1 |
| Stables, J | 1 |
| Kamiński, K | 1 |
| Zagaja, M | 1 |
| Rapacz, A | 1 |
| Łuszczki, JJ | 1 |
| Andres-Mach, M | 1 |
| Abram, M | 1 |
| Obniska, J | 1 |
| Berntson, L | 1 |
| Liminga, G | 1 |
| Palazzo, E | 1 |
| Rimoli, MG | 1 |
| De Chiaro, M | 1 |
| Guida, F | 1 |
| Melisi, D | 1 |
| Curcio, A | 1 |
| de Novellis, V | 1 |
| Marabese, I | 1 |
| Rossi, F | 1 |
| Abignente, E | 1 |
| Maione, S | 1 |
4 other studies available for ethosuximide and Ache
| Article | Year |
|---|---|
Discovery of 4-aminobutyric acid derivatives possessing anticonvulsant and antinociceptive activities: a hybrid pharmacophore approach.
Topics: Analgesics; Animals; Anticonvulsants; Disease Models, Animal; gamma-Aminobutyric Acid; Hyperalgesia; | 2007 |
New hybrid molecules with anticonvulsant and antinociceptive activity derived from 3-methyl- or 3,3-dimethyl-1-[1-oxo-1-(4-phenylpiperazin-1-yl)propan-2-yl]pyrrolidine-2,5-diones.
Topics: Analgesics; Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Elec | 2016 |
Severe Raynaud's phenomenon from ethosuximide raised concern over possible onset of systemic vasculitis: a case report.
Topics: Child; Connective Tissue Diseases; Ethosuximide; Female; Fingers; Humans; Pain; Raynaud Disease; Sys | 2022 |
Intra-periaqueductal grey microinjections of an imidazo[1,2-b]pyridazine derivative, DM2, affects rostral ventromedial medulla cell activity and shows antinociceptive effect.
Topics: Action Potentials; Analgesics; Animals; Anticonvulsants; Blood Pressure; Dose-Response Relationship, | 2010 |